Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres
H Sprott, S Salemi, R E Gay, L A Bradley, G S Alarcón, S J Oh, B A Michel, S Gay, H Sprott, S Salemi, R E Gay, L A Bradley, G S Alarcón, S J Oh, B A Michel, S Gay
Abstract
Objective: To determine whether there is evidence of increased DNA fragmentation and ultrastructural changes in muscle tissue of patients with fibromyalgia (FM) compared with healthy controls.
Methods: Muscle tissues from 10 community residents with FM and 10 age and sex matched healthy controls were examined "blindly" for the presence of DNA fragmentation by two different methods: terminal deoxynucleotidyl transferase (TdT) staining (TUNEL) and the FragEL-Klenow DNA fragmentation detection kit. Ultrastructural analysis of tissue was performed by electron microscopy.
Results: DNA fragmentation was detected by both methods in 55.4 (SEM 2.5)% of the nuclei in muscle tissue of patients with FM compared with 16.1 (4.1)% (p<0.001) of the nuclei in healthy controls. Contrary to expectation, no typical features of apoptosis could be detected by electron microscopy. The myofibres and actin filaments were disorganised and lipofuscin bodies were seen; glycogen and lipid accumulation were also found. The number of mitochondria was significantly lower in patients with FM than in controls and seemed to be morphologically altered.
Conclusion: The ultrastructural changes described suggest that patients with FM are characterised by abnormalities in muscle tissue that include increased DNA fragmentation and changes in the number and size of mitochondria. These cellular changes are not signs of apoptosis. Persistent focal contractions in muscle may contribute to ultrastructural tissue abnormalities as well as to the induction and/or chronicity of nociceptive transmission from muscle to the central nervous system.
Figures
References
- Clin Exp Rheumatol. 2001 Jul-Aug;19(4):453-5
- J Rheumatol. 1999 Jul;26(7):1570-6
- J Rheumatol. 2002 Jun;29(6):1287-95
- Arthritis Rheum. 2002 May;46(5):1333-43
- BMJ. 2002 Jul 27;325(7357):185
- Curr Opin Rheumatol. 2003 Mar;15(2):145-50
- J Ultrastruct Res. 1969 Jan;26(1):31-43
- Pain. 1975 Sep;1(3):277-99
- Nature. 1980 Apr 10;284(5756):555-6
- Int Rev Cytol. 1980;68:251-306
- Proc Natl Acad Sci U S A. 1983 Oct;80(20):6361-5
- Am J Med. 1986 Sep 29;81(3A):38-42
- Rheum Dis Clin North Am. 1989 Feb;15(1):1-18
- Rheum Dis Clin North Am. 1989 Feb;15(1):115-34
- J Rheumatol. 1989 Jan;16(1):97-101
- Arch Neurol. 1989 Oct;46(10):1121-3
- Arthritis Rheum. 1990 Feb;33(2):160-72
- Arch Toxicol. 1991;65(6):437-44
- Scand J Rheumatol. 1991;20(5):336-43
- J Cell Biol. 1992 Nov;119(3):493-501
- Arthritis Rheum. 1994 Jun;37(6):794-800
- Arthritis Rheum. 1994 Jun;37(6):801-7
- Arthritis Rheum. 1994 Nov;37(11):1583-92
- Arthritis Rheum. 1994 Nov;37(11):1593-601
- Arthritis Rheum. 1995 Jan;38(1):19-28
- Pain. 2000 Apr;85(3):483-91
- Pain. 2000 Aug;87(2):201-11
- Rheumatology (Oxford). 2000 Oct;39(10):1121-5
- Cell Mol Life Sci. 2000 Oct;57(11):1535-41
- Pain. 2001 Mar;91(1-2):165-75
- Arthritis Rheum. 1995 Jul;38(7):926-38
- FEBS Lett. 1995 Oct 16;373(3):291-5
- Scand J Rheumatol. 1995;24(6):395-6
- Arthritis Rheum. 1996 Mar;39(3):436-45
- Ann N Y Acad Sci. 1996 Jun 15;786:24-43
- Arthritis Rheum. 1998 Mar;41(3):406-13
- Am J Med Sci. 1998 Jun;315(6):405-12
- Arthritis Rheum. 2001 Aug;45(4):362-71
Source: PubMed